The Q2 2026 Whole Life and VUL Surge: An Agency Playbook
A large independent agency running a dozen producers is watching whole life and VUL applications spike in Q2 2026, the sales surge this playbook addresses through realigned prospecting and placement operations. LIMRA reports whole life premium rose 9% and VUL rose 11 to 13% year over year, so routing and ramp plans must shift now.
What happened to whole life and VUL sales in Q2 2026?
Whole life and VUL sales both grew in Q2 2026 while overall market growth slowed. LIMRA reports total individual life new annualized premium rose 3% year over year to $4.7 billion, but whole life premium rose 9% to $1.77 billion and VUL premium rose 11% to 13% to roughly $800 million.
The gap between those numbers is the story for a principal running a shared pipeline: total policies sold grew 8% while total premium grew only 3%, meaning the average new case got smaller even as volume rose. LIMRA's release, "U.S. Individual Life Insurance Sales Continue Growth Trend in the Second Quarter Led by Whole Life and VUL," is the anchor for these figures.
| Metric | Q2 2026 value | Year-over-year change |
|---|---|---|
| Total individual life new annualized premium | $4.7 billion | +3% |
| Total policies sold | Not disclosed | +8% |
| Whole life new annualized premium | $1.77 billion | +9% |
| Whole life policy count | Not disclosed | +10% |
| VUL new annualized premium | $800 to $811 million | +11% to +13% |
| Whole life share of total new premium | 37% | n/a |
For a large agency, that policy-count-versus-premium gap usually means more final expense and smaller VUL tickets moving through the same producers who were closing bigger cases a year ago, which changes how you staff and route the floor, not just how you script the call.
How did whole life compare to the total market?
Whole life became the largest single product category in Q2 2026, at 37% of total new annualized premium. LIMRA attributed the whole life gain largely to network marketing distribution, a channel note worth reading closely if your agency's lead sources overlap with that world.
LIMRA's release described the quarter's whole life gain as "largely driven by network marketing distribution," which matters for a principal deciding where to spend acquisition budget this quarter. Context from the prior twelve months backs up the trend: whole life set a full-year sales record in 2025 at $6.4 billion in new premium, up 7%, with policy count up 12%, inside a total individual life market that topped $17.5 billion for the year, also a record, per LIMRA. The long-run historical average annual growth rate for individual life new premium is 3.1%, per LIMRA's 2026 forecast, so a quarter running whole life growth at 9% to 10% on both premium and policy count is running well above trend, not just a normal seasonal bump.
What is LIMRA's outlook for VUL sales in 2026?
LIMRA forecasts VUL sales growth will moderate through the rest of 2026, projecting a range of 1% to 7% for the full year because of expected equity market volatility. That compares with 12% VUL premium growth in Q1 2026 and 11% to 13% growth in Q2 2026.
VUL premium plus excess ran $729 million in Q1 2026 and roughly $800 million to $811 million in Q2 2026 depending on the reporting source, per LIMRA and beinsure. LIMRA's full-year 2026 outlook puts overall individual life new annualized premium growth at 2% to 6%, and 2025 VUL sales already hit $2.6 billion, up 17%, with policy count up 5%. The forecast moderation is a market call about equities, not a call about producer capacity, and a large agency's own VUL pipeline can still outrun the market average if lead routing and licensing match the demand.
Why split whole life and VUL prospecting from term?
A large agency should run whole life and VUL as separate prospecting tracks because the buyers, sales cycles, and licensing requirements differ. Whole life leads skew toward final expense and network marketing sources, while VUL conversations involve equity market context and often require a producer holding a securities registration.
A single script and a single lead source treat three different buyers as one. Term buyers are usually price and coverage-amount driven with a short cycle; whole life buyers, especially final expense, respond to simplicity and speed to contact; VUL buyers need a longer, more consultative conversation and a licensed producer who can legally have it. Blending these into one queue on a shared pipeline is how a fast-growing floor ends up with the wrong producer on the wrong call. If you are restructuring how one team runs prospecting across product lines, see how independent agency operations typically separate these workflows without adding headcount.
How should a shared pipeline route permanent-life leads?
A shared pipeline should route whole life and VUL leads by producer license, product fluency, and speed, not by simple round robin. Final expense whole life leads need instant contact within minutes, while VUL leads need routing straight to a securities-licensed producer before the case ages.
Routing logic that ignores license status is an outsized risk once VUL volume rises, since an unlicensed producer working a securities-linked lead is a compliance problem, not just a lost sale. Kadence, AI built to grow life insurance distribution, front to back office, pulls every inbound lead from every source into one shared pipeline and has its Voice AI answer, text, and engage the lead before ten seconds pass, then hands it to a routing rule that already knows which producers are cleared for VUL and which are fastest on final expense. That single-pipeline structure is also what gives an owner one place to see whether whole life leads are sitting unworked while VUL leads pile up on the two producers licensed to take them.
What ramp do new producers need for whole life and VUL?
New producers need a longer ramp for VUL than for whole life because VUL sales require comfort with market-linked products and a securities registration. Agencies scaling headcount during this surge should plan roughly 8 to 12 weeks of paired calls and shadowed appointments before a new producer runs permanent-life leads solo.
A ramp curve that treats whole life and VUL identically under-trains new producers on VUL and over-trains them on whole life, wasting both lead spend and manager time. A practical staged approach:
| Ramp stage | Whole life timeline (weeks) | VUL timeline (weeks) | Producer milestone |
|---|---|---|---|
| Shadowing | 1 to 2 | 1 to 3 | Shadows a senior producer on live calls |
| Coached calls | 3 to 4 | 4 to 6 | Takes warm transfers with live coaching |
| Independent with review | 5 to 6 | 7 to 10 | Runs own leads, manager reviews every call |
| Full ownership | 7 or more | 11 or more | Owns pipeline, reviewed only in weekly KPI meeting |
Using a shorter whole life ramp lets a growing agency put new producers on final expense volume fast, while VUL leads stay with tenured, licensed producers until the newer hires clear the longer curve.
How do you know the surge is becoming placed business?
An agency confirms the surge is turning into placed business by tracking placement rate, not application volume alone. LIMRA reports policy count rose 8% in Q2 2026 while premium rose only 3%, meaning average case size is shrinking, so owners should track placed premium per rep, not just apps taken.
A floor that is busy is not automatically a floor that is paid. Watch the gap between applications submitted and policies actually placed and paying, especially on VUL, where underwriting and suitability review can run longer than a whole life final expense case. Kadence's back office already tracks commissions as they post and is adding visibility into persistency and downline production, giving an owner one place to see whether this quarter's applied volume is showing up as paid, staying-on-the-books revenue instead of aging in underwriting.
What compliance risks come with more permanent-life outreach?
Heavier whole life and VUL outreach raises TCPA and Do Not Call exposure simply because call and text volume rises with lead volume. Every outbound contact still needs prior express consent tied to that specific number, honored opt outs, and National DNC suppression, and agencies should confirm current requirements with counsel before scaling dialing.
VUL outreach adds a second layer: any communication that touches securities suitability needs a licensed, registered producer on the call, not just a licensed insurance producer. Kadence's outbound calling layer logs written consent at the number level and checks it against the National Do Not Call registry and internal opt-out lists before a producer's line ever dials, which matters more once floor-wide call volume climbs during a surge like this one. None of this is legal advice; confirm current TCPA, DNC, and securities-suitability requirements with counsel before scaling outreach on either product line.
How should lead distribution shift as case sizes drop?
Lead distribution should shift toward smaller, more frequent allocations as average case size drops. LIMRA data show policies sold grew 8% in Q2 2026 against 3% premium growth, so agencies should route more, smaller-ticket final expense and VUL leads per producer per day rather than fewer large cases per week.
A quota built around last year's average case size will look broken this quarter even if the team is working harder and closing more policies, simply because each policy is worth less on average. Recalculate per-rep volume targets around policy count as well as premium, and rebalance lead allocation weekly rather than monthly so no single producer ends up overloaded with final expense volume while another sits idle waiting on a VUL lead. For a broader look at how buyers are evaluating permanent life products right now, see this roundup of buyer questions on life insurance, which is useful context for training new producers on objections.
What should owners track weekly during this surge?
Agency owners should track five weekly numbers during this surge: speed to lead, contact rate, appointment rate, placement rate, and average case size by product. Watching these across the whole team, not per producer only, shows whether the Q2 2026 whole life and VUL surge is becoming durable revenue or just more open pipeline.
| Weekly KPI | What it measures | Why it matters during the surge |
|---|---|---|
| Speed to lead (minutes) | Time from lead capture to first live contact | LIMRA-adjacent research on buyer behavior shows the first responder usually wins the lead |
| Contact rate (%) | Share of assigned leads reached at least once | Flags routing or dialing gaps across the floor |
| Appointment rate (%) | Share of contacts that book a follow-up meeting | Shows whether whole life and VUL scripts are converting interest |
| Placement rate (%) | Share of applications that place, not just submit | Separates real growth from a backlog stuck in underwriting |
| Average case size by product (USD) | Placed premium per policy, whole life vs VUL | Confirms whether smaller final expense tickets are diluting revenue per case |
For more on how industry sales figures like these are compiled and verified, see the research methodology behind this data. to see how Kadence keeps these five numbers visible across every producer on your floor as volume shifts toward whole life and VUL.
Sources
- U.S. Individual Life Insurance Sales Continue Growth Trend in the Second Quarter Led by Whole Life and VUL
- US Life Insurance Sales Rise as Whole Life Leads Growth
- What life insurance are clients buying? New data reveals the trends
- Life Insurance Sales Keep Climbing in Q2 2026
- Double-Digit Growth Drives Individual Life Insurance New Premium to Set New Sales Record in 2025
- LIMRA: U.S. Individual Life Insurance New Premium Tops $17.5 Billion to Set New Sales Record in 2025
- U.S. Individual Life Insurance Sales Post Strong Growth in the First Quarter
- Life and annuity sales to continue 'pretty remarkable' growth in 2026
Key figures: LIMRA U.S. Individual Life Sales Data, Q1 2026 to Q2 2026
| Metric | Value |
|---|---|
| Whole life new annualized premium, Q2 2026 | $1.77 billion, +9% YoY (LIMRA) |
| VUL new annualized premium, Q2 2026 | $800 to $811 million, +11% to +13% YoY (LIMRA/Beinsure) |
| Total individual life new annualized premium, Q2 2026 | $4.7 billion, +3% YoY (LIMRA) |
| Total policies sold, Q2 2026 | +8% YoY (LIMRA) |
| Whole life share of total new premium, Q2 2026 | 37% (LIMRA) |
| Whole life full-year record, 2025 | $6.4 billion new premium, +7% YoY (LIMRA) |
| VUL full-year sales, 2025 | $2.6 billion new premium, +17% YoY (LIMRA) |
| LIMRA 2026 full-year VUL growth forecast | 1% to 7% growth (LIMRA) |
Frequently Asked Questions
Did term life sales also grow in Q2 2026?
Yes, term life also posted gains in Q2 2026 alongside whole life and VUL, per LIMRA's Q2 2026 sales release. Fixed universal life sales declined again in the same quarter, continuing a longer slide for that product category relative to the rest of the individual life market.
Is the whole life growth coming from new agents or existing books?
LIMRA attributes the Q2 2026 whole life gain largely to network marketing distribution channels, not simply renewals on existing books. That points to new producer activity and final expense volume driving growth, which means agencies recruiting and ramping producers now are positioned to capture more of that gain.
How long might the whole life and VUL surge last?
LIMRA's 2026 outlook forecasts overall individual life new premium growth of 2% to 6% for the full year, above the long run historical average of 3.1%, while VUL growth is expected to moderate to 1% to 7% because of equity market volatility. That points to continued but uneven growth through year end.
Written by
Kadence Team
Kadence is AI built to grow life insurance distribution, front to back office, purpose-built for producers, agencies, and IMO networks. We write about speed to lead, AI search, back-office tracking, and the systems that help producers and agencies win more policies.
Reviewed by the Kadence Team.
Book a demo
